Health Affairs, 26, no. 3 (2007): 681-683 doi: 10.1377/hlthaff.26.3.681 © 2007 by Project HOPE	New Online   New Issue: China & India   Obesity In China   Pay Cuts For Medicare Docs   Access To Care Woes

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Meltzer, D. Search for Related Content PubMed Articles by Meltzer, D. Related Collections Consumer Issues Legal/Regulatory Issues Medicare Pharmaceuticals Physicians Research And Technology

Perspectives

PERSPECTIVE

Risks And Benefits Of Risk-Management Plans

Scott Gottlieb criticizes the emphasis on the greater use of risk-management plans in the recent Institute of Medicine (IOM) report on drug safety and the Kennedy-Enzi bill as impractical, failing to recognize the underlying causes of recent drug risk concerns, having the potential to create barriers to care, and interfering unnecessarily in physician decision making. These are worthy concerns but ones that need to be considered in the context of specific regulatory decisions for individual drugs. This is precisely the motivation for calls for greater attention to the potential use of risk-management plans in drug evaluation.

                      What's this?